Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 12 | 2025 | 258 | 2.600 |
Why?
|
| Hypoglycemic Agents | 10 | 2023 | 159 | 1.630 |
Why?
|
| Insulin | 5 | 2012 | 131 | 0.940 |
Why?
|
| Sulfonylurea Compounds | 2 | 2019 | 17 | 0.700 |
Why?
|
| Metformin | 2 | 2019 | 30 | 0.680 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 5 | 0.650 |
Why?
|
| Middle Aged | 11 | 2025 | 1544 | 0.580 |
Why?
|
| Adult | 10 | 2025 | 1402 | 0.550 |
Why?
|
| Humans | 20 | 2025 | 4931 | 0.540 |
Why?
|
| Glycated Hemoglobin A | 5 | 2021 | 64 | 0.510 |
Why?
|
| Cholesterol | 3 | 2013 | 29 | 0.490 |
Why?
|
| Minority Groups | 2 | 2012 | 53 | 0.470 |
Why?
|
| Female | 12 | 2025 | 2964 | 0.470 |
Why?
|
| Insulin Resistance | 3 | 2012 | 63 | 0.460 |
Why?
|
| Aged | 7 | 2025 | 1188 | 0.440 |
Why?
|
| Male | 11 | 2025 | 2620 | 0.420 |
Why?
|
| Thiazolidinediones | 2 | 2011 | 26 | 0.410 |
Why?
|
| Hyperlipidemias | 1 | 2013 | 15 | 0.410 |
Why?
|
| Insurance, Health | 1 | 2013 | 23 | 0.410 |
Why?
|
| Anticholesteremic Agents | 1 | 2013 | 20 | 0.400 |
Why?
|
| Poverty | 1 | 2012 | 53 | 0.390 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 50 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 93 | 0.390 |
Why?
|
| Triazoles | 1 | 2011 | 12 | 0.370 |
Why?
|
| Pyrazines | 1 | 2011 | 16 | 0.370 |
Why?
|
| Insulin, Isophane | 1 | 2010 | 3 | 0.350 |
Why?
|
| Treatment Outcome | 6 | 2023 | 402 | 0.340 |
Why?
|
| Blood Glucose | 4 | 2020 | 179 | 0.300 |
Why?
|
| Hypoglycemia | 2 | 2025 | 29 | 0.270 |
Why?
|
| Cholesterol, LDL | 2 | 2006 | 34 | 0.270 |
Why?
|
| Adolescent | 4 | 2013 | 569 | 0.260 |
Why?
|
| Lipids | 1 | 2006 | 34 | 0.260 |
Why?
|
| Atherosclerosis | 1 | 2006 | 26 | 0.250 |
Why?
|
| Young Adult | 3 | 2013 | 382 | 0.250 |
Why?
|
| Double-Blind Method | 5 | 2025 | 81 | 0.230 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 3 | 0.230 |
Why?
|
| Phytotherapy | 1 | 2004 | 5 | 0.230 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 58 | 0.210 |
Why?
|
| Nutrition Surveys | 2 | 2017 | 47 | 0.200 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2023 | 28 | 0.200 |
Why?
|
| Prospective Studies | 2 | 2020 | 229 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 358 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 154 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 160 | 0.170 |
Why?
|
| Glycemic Index | 1 | 2020 | 4 | 0.170 |
Why?
|
| Antimalarials | 1 | 2019 | 3 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 42 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2019 | 18 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 170 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2019 | 53 | 0.160 |
Why?
|
| United States | 3 | 2017 | 764 | 0.150 |
Why?
|
| Accelerometry | 1 | 2017 | 3 | 0.140 |
Why?
|
| Self Report | 1 | 2017 | 26 | 0.140 |
Why?
|
| Exercise | 1 | 2017 | 41 | 0.140 |
Why?
|
| Risk Factors | 2 | 2012 | 593 | 0.130 |
Why?
|
| Testosterone | 2 | 2006 | 43 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2013 | 59 | 0.100 |
Why?
|
| Cultural Characteristics | 1 | 2012 | 7 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2012 | 21 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 35 | 0.100 |
Why?
|
| Perception | 1 | 2012 | 14 | 0.100 |
Why?
|
| Glucagon-Like Peptides | 2 | 2023 | 3 | 0.100 |
Why?
|
| Logistic Models | 1 | 2012 | 117 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 45 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2013 | 127 | 0.100 |
Why?
|
| Los Angeles | 1 | 2012 | 244 | 0.090 |
Why?
|
| Smoking | 1 | 2012 | 59 | 0.090 |
Why?
|
| Sitagliptin Phosphate | 1 | 2011 | 6 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 2 | 0.090 |
Why?
|
| Cities | 1 | 2010 | 5 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2010 | 10 | 0.090 |
Why?
|
| Insulin, Long-Acting | 1 | 2010 | 14 | 0.090 |
Why?
|
| Weight Gain | 1 | 2010 | 27 | 0.090 |
Why?
|
| Insulin Glargine | 1 | 2010 | 15 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 91 | 0.090 |
Why?
|
| African Americans | 1 | 2012 | 256 | 0.080 |
Why?
|
| Apolipoproteins B | 2 | 2006 | 6 | 0.080 |
Why?
|
| Cholesterol, HDL | 2 | 2006 | 22 | 0.080 |
Why?
|
| Triglycerides | 2 | 2006 | 45 | 0.080 |
Why?
|
| Demography | 1 | 2006 | 19 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 2 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2006 | 67 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 14 | 0.060 |
Why?
|
| Weight Loss | 1 | 2006 | 32 | 0.060 |
Why?
|
| Cytokines | 1 | 2006 | 60 | 0.060 |
Why?
|
| Oxadiazoles | 1 | 2025 | 1 | 0.060 |
Why?
|
| Fluorine Compounds | 1 | 2025 | 1 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 36 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2025 | 126 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 38 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2004 | 29 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2006 | 513 | 0.060 |
Why?
|
| Chromans | 1 | 2004 | 1 | 0.050 |
Why?
|
| Annexin A2 | 1 | 2004 | 1 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 8 | 0.050 |
Why?
|
| Muscle Proteins | 1 | 2004 | 12 | 0.050 |
Why?
|
| HIV Infections | 1 | 2006 | 167 | 0.050 |
Why?
|
| Adipocytes | 1 | 2004 | 22 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2023 | 6 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 1 | 0.050 |
Why?
|
| Body Weight | 1 | 2023 | 80 | 0.050 |
Why?
|
| Quality of Life | 1 | 2004 | 139 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2001 | 8 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 2 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Selenium | 1 | 2000 | 1 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2000 | 8 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 11 | 0.040 |
Why?
|
| Glycation End Products, Advanced | 1 | 2020 | 3 | 0.040 |
Why?
|
| Fructosamine | 1 | 2020 | 3 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2000 | 12 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 167 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 202 | 0.040 |
Why?
|
| Morbidity | 1 | 2017 | 17 | 0.040 |
Why?
|
| Animals | 2 | 2012 | 1369 | 0.030 |
Why?
|
| Hypogonadism | 1 | 2012 | 10 | 0.020 |
Why?
|
| Endocrine System Diseases | 1 | 2012 | 6 | 0.020 |
Why?
|
| Biological Transport | 2 | 2004 | 15 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2012 | 35 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2006 | 4 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 10 | 0.020 |
Why?
|
| Thrombosis | 1 | 2006 | 7 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 76 | 0.020 |
Why?
|
| Comorbidity | 1 | 2006 | 123 | 0.020 |
Why?
|
| California | 1 | 2006 | 161 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 122 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 5 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 5 | 0.010 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2004 | 5 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2004 | 12 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 22 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 44 | 0.010 |
Why?
|
| Apolipoproteins C | 1 | 2002 | 1 | 0.010 |
Why?
|
| Triptorelin Pamoate | 1 | 2002 | 1 | 0.010 |
Why?
|
| Apolipoprotein C-III | 1 | 2002 | 1 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 555 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 28 | 0.010 |
Why?
|
| Estradiol | 1 | 2002 | 47 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 58 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 1 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2000 | 2 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 4 | 0.010 |
Why?
|
| Cell Size | 1 | 2000 | 2 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 3 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 35 | 0.010 |
Why?
|
| Amino Acids | 1 | 2000 | 15 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 35 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 58 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 34 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 34 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2000 | 30 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 51 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 117 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 144 | 0.010 |
Why?
|